Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day

Novartis executives are meeting investors and analysts today at an event in London, U.K., to showcase the company’s ‘pure play’ innovative medicines strategy and focused Research and Development pipeline.

“Novartis has now completed its transformation into a ‘pure-play’ innovative medicines company, delivering robust increases in core margin and free cash flow, while also continuing strong operational performance. We remain committed to executing our focused strategy, and creating significant shareholder value in the short-, mid-, and long-term as illustrated by our upgraded mid-term sales guidance to 5% CAGR and ~40%+ core operating income margin.”, said Vas Narasimhan M.D., CEO of Novartis. “ Our pipeline is focused on delivering high value assets across our four core therapeutic areas and fully realizing the potential of our advanced technology platforms, which could unlock future substantial growth.”

Novartis today outlines progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology), two plus three technology platforms (Chemistry, Biotherapeutics, xRNA, Radioligand, Gene & Cell Therapy) in four priority geographies (US, China, Germany, Japan).

Strengthening R&D pipeline, improving productivity
The company continues to make significant progress in improving the performance of R&D through active prioritization of the pipeline to focus on high-value assets, and driving operational excellence within the organization. This has enabled increased resourcing for priority projects and strengthening functional capabilities.

Across Biomedical Research and Development, resources have been streamlined to maximize focus and enhance competencies. The strong, streamlined portfolio now comprises 103 projects1 including 46 NMEs, with up to 15 key submissions for regulatory approval expected in the 2024-2027 timeframe, each targeted to address major unmet needs and with significant sales potential.

Four core Therapeutic Areas; advanced technology platforms*
Oncology disease areas include breast, prostate and lung cancer as well as CML, NHL, MM, AML, MDS, PNH, ITP, wAIHA.

  • Submissions planned by 2027 include Kisqali for HR+/HER2- breast cancer, in the adjuvant setting, Pluvicto for mCRPC in both the pre-taxane setting and for mHSPC, and Scemblix in first line CML, as well as iptacopan for PNH.
  • Radioligand therapy in solid tumors offers patients better efficacy with lower side effects.

Cardiovascular, Renal and Metabolic (CRM) disease areas include heart failure & hypertension, atherosclerosis, rare renal diseases and acute kidney injury.

  • Submissions planned by 2027 include iptacopan, atrasentan and zigakibart for treatment of IgAN, iptacopan for the treatment of C3G, pelacarsen to lower Lp(a) for CV risk reduction and Leqvio for pediatric hyperlipidemia.
  • siRNA offers improved adherence while maintaining efficacy in cardiovascular diseases.

Immunology disease areas include psoriasis, psoriatic arthritis, spondylitis / spondylarthritis, HS, CSU, CINDU, Sjögren’s, SLE, LN and food allergy.

  • Submissions planned by 2027 include multiple filings to extend Cosentyx indications, remibrutinib for CSU and CINDU and ianalumab for Sjögren’s syndrome.
  • CAR-T offers potential in SLE, Sjögren’s, severe rheumatoid arthritis.

Neuroscience disease areas include multiple sclerosis, neurodegeneration (Alzheimer’s and Parkinson’s) and neuromuscular disease (building on Spinal Muscular Atrophy, including ALS).

  • Submissions planned by 2027 include an intrathecal formulation for Zolgensma and remibrutinib for multiple sclerosis.
  • Technologies delivering nucleic assets to the brain have shown promising data.

Source link